GlaxoSmithKline (GSK) and Theravance, Inc. have proudly announced that the Therapeutic Goods Administration (TGA) has approved Anoro Ellipta (umeclidinium/vilanterol) as a maintenance bronchodilator treatment to relieve symptoms in Australian adult patients with chronic obstructive pulmonary disease (COPD) which is also known as “chronic bronchitis,” “smoker’s cough” or emphysema”. 

Anoro is a combination treatment comprising two bronchodilators (medicines that help make breathing easier), umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler, the Ellipta. 

GSK Associate Medical Director, Dr Navin Singh says the company is committed to bringing new respiratory therapy options to Australian patients. 

“There are many Australians living with COPD for whom the disease represents a significant burden. GSK is committed to developing a range of new therapeutic options that provide physicians with treatment choices when considering individual patient needs.” 

“We are delighted by the TGA approval of Anoro Ellipta which provides a new alternative for COPD patients for whom dual bronchodilator treatment in a single inhaler may be appropriate,” said Dr Singh.

For more details, go to: http://www.gsk.com.au/media-centre_detail.aspx?view=752